Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

PALO ALTO, CA, UNITED STATES, August 13, 2025 / EINPresswire.com / -- Baylink Biosciences, a biotechnology company pioneering next-generation antibody-drug conjugate (ADC) technologies, today ...

Synaffix, a company of Swiss drugmaker Lonza, has entered into a licensing agreement with South Korean biopharmaceutical firm Qurient to develop a dual-payload antibody-drug conjugate (ADC). Synaffix ...

Two different warheads may be better than one on antibody–drug conjugates (ADCs), suspect a growing cohort of companies. Two companies are already testing this dual-payload ADC strategy in cancer ...

TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, ...

NERVIANO, Italy & MILAN--(BUSINESS WIRE)--Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with ...

London-based deal experts are the advisors for this collaboration and the ongoing partnering efforts for IntoCell's platform technologies and its lead programme, B7-H3 ADC. IntoCell, a South Korean ...

One of the fastest-growing segments of pharmaceuticals, as highlighted at the 2024 J.P. Morgan Healthcare Conference, is the antibody-drug conjugate (ADC) segment. ADCs consist of four main elements: ...

Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study Antibody-drug conjugates (ADCs) are ...

The emergence of antibody-drug conjugates (ADCs) has seen them become a promising class of anticancer therapeutics, exhibiting better precision and reduced off-target toxicity in targeting cancer ...